Group 1 - The core viewpoint of the article highlights that EnGene Biotech-B (09606) has seen its stock price rise over 10%, reaching a new high of 480 HKD, following the announcement of its inclusion in the Hang Seng Composite Index and the Stock Connect program [1] - The inclusion in the Hang Seng Composite Index and the Stock Connect program is expected to enhance the company's investor base and increase trading liquidity [1][1] - The company reported a revenue of 1.23 billion HKD for the interim period, primarily due to upfront payments from licensing agreements, including 50 million USD from Avenzo and 20 million USD from 3SBio [1][1] Group 2 - The company experienced a significant increase in losses, attributed to fair value changes in financial liabilities measured at fair value through profit or loss [1] - The company holds 3.75 billion HKD in cash, which is deemed sufficient to support clinical and early-stage R&D investments for the next 3 to 5 years [1][1] - The collaboration pipeline with BioNTech is progressing steadily, with early-stage molecules expected to show potential [1]
映恩生物-B涨超10%再破顶 进入港股通有望获内资追捧 现金储备充足可支持未来数年研发